RETIN-A
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RETIN-A (RETIN-A).
Retin-A (tretinoin) binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene expression involved in cell differentiation, proliferation, and inflammation. It increases epidermal turnover, reduces comedone formation, and stimulates collagen synthesis.
| Metabolism | Topical tretinoin is metabolized in the skin and systemically via hepatic cytochrome P450 enzymes (CYP2C8, CYP2C9, CYP2B6, CYP3A4) to oxidative metabolites (e.g., 4-oxo-retinoic acid), which are further conjugated and excreted in urine and bile. |
| Excretion | After topical application, systemic absorption is minimal. The absorbed fraction is metabolized in the liver via cytochrome P450 enzymes and excreted in bile and urine as glucuronide conjugates. Renal excretion accounts for <1% of the applied dose; fecal excretion of metabolites is the primary route (<5% of applied dose). |
| Half-life | Terminal elimination half-life is approximately 0.5-2 hours for the parent drug. Clinical context: Due to rapid clearance, systemic accumulation is negligible with topical use; effects persist due to retinoid-induced gene expression changes. |
| Protein binding | Greater than 95% bound, primarily to albumin (≈90%) and lipoproteins (≈10%). |
| Volume of Distribution | When absorbed systemically, Vd is approximately 1-2 L/kg, indicating extensive tissue distribution, though systemic exposure is negligible with topical use. |
| Bioavailability | Topical: Systemic bioavailability is <1% of the applied dose (range 0.5-5% depending on formulation and skin condition). Oral: Not applicable (not administered orally). |
| Onset of Action | Topical: Clinical improvement in acne vulgaris is typically observed within 2-4 weeks of daily application. Full therapeutic effect may require 8-12 weeks. |
| Duration of Action | Effects persist for weeks after discontinuation due to alterations in gene expression and cell turnover. Clinical improvement lasts as long as treatment continues; after stopping, effects gradually wane over 4-8 weeks. |
| Molecular Weight | 300.44 |
Apply a thin layer to affected areas once daily at bedtime. Initial concentration typically 0.025% cream or 0.01% gel; titrate based on tolerability.
| Dosage form | SWAB |
| Renal impairment | No specific renal dose adjustment required; systemic absorption is minimal after topical application. |
| Liver impairment | No specific hepatic dose adjustment required; avoid use in severe hepatic impairment due to potential accumulation of excipients. |
| Pediatric use | Not recommended for use in children younger than 12 years of age due to lack of safety and efficacy data. For adolescents 12 years and older, use same as adult dosing. |
| Geriatric use | Use with caution; skin may be more sensitive. Consider lower strength (e.g., 0.025% cream) and monitor for irritation. Avoid excessive application. |
| 1st trimester | Topical tretinoin is contraindicated in the first trimester due to risk of retinoid embryopathy; systemic exposure is minimal but teratogenic potential exists. |
| 2nd trimester | Avoid use in second trimester; although systemic absorption is low, alternative therapies are preferred. |
| 3rd trimester | Avoid use in third trimester; theoretical risk of fetal effects persists. |
Clinical note
Comprehensive clinical and safety monograph for RETIN-A (RETIN-A).
| Placental transfer | Minimal with topical use; studies show low plasma concentrations (below 0.01 ng/mL) after topical application. |
| Breastfeeding | Topical application likely results in negligible systemic absorption; however, avoid application to breast area and use with caution. Monitor infant for irritation. |
■ FDA Black Box Warning
No FDA black box warnings for topical tretinoin. However, systemic retinoids (e.g., isotretinoin) carry warnings for teratogenicity and depression.
| Serious Effects |
Hypersensitivity to tretinoin or any componentPregnancy
| Precautions | Increased sensitivity to sunlight; avoid prolonged sun exposure and use sunscreen, Initial exacerbation of acne (retinoid flare) may occur, Avoid application on eczematous, sunburned, or irritated skin, Use with caution in patients with eczema or chronic skin conditions, Not for use in pregnant women (Pregnancy Category C); potential teratogenicity if significant systemic absorption |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol intake as it may exacerbate skin dryness. |
Loading safety data…
| Lactation Rating |
| L3 (Moderate Safety) |
| Teratogenic Risk | Retin-A (tretinoin) is FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Oral tretinoin is known to be teratogenic in humans; however, topical application is associated with minimal systemic absorption (<10%). Case reports have not demonstrated an increased risk of major birth defects with topical use, but the theoretical risk remains. Caution is advised, and use during pregnancy should be avoided unless clearly needed. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond routine prenatal care, as systemic exposure from topical tretinoin is minimal. However, if used inadvertently during pregnancy, ultrasound monitoring for fetal anomalies may be considered. |
| Fertility Effects | No significant effects on fertility have been reported with topical tretinoin. Systemic retinoids can affect spermatogenesis and ovulation, but topical use is unlikely to have an impact due to low absorption. |
| Clinical Pearls | Initiate with lower concentration (0.025% cream) to minimize irritation; apply pea-sized amount for entire face; use only at night due to photolability; avoid concurrent use of other topical irritants (e.g., benzoyl peroxide, salicylic acid); can cause temporary worsening of acne (purge) in first 4-6 weeks; caution in pregnancy (topical use is category C; oral retinoids contraindicated). |
| Patient Advice | Apply a thin layer to completely dry skin at night, 20-30 minutes after washing. · Use sunscreen daily (SPF 30+) and avoid excessive sun exposure. · May cause redness, peeling, and burning initially; use moisturizer to reduce irritation. · Do not apply to broken, sunburned, or eczematous skin. · Avoid waxing or using harsh exfoliants while on this medication. · Therapeutic effects may not be seen for 8-12 weeks. · Pregnancy or planning pregnancy should be discussed with doctor. · Do not use more than prescribed; overuse increases side effects. |